LKT Labs

Biochemicals for Life Science Research

TG100-115

TG100-115

Product ID T2402
Cas No. 677297-51-7
Purity ≥98%
Product Unit SizeCostQuantityStock
1 mg $146.00 In stock
5 mg $292.00 In stock
10 mg $470.00 In stock
Bulk Quote

Quicklinks

Description

TG100-115 is an inhibitor of p110δ PI3K and p110γ PI3K that exhibits anti-inflammatory and anti-asthma activities. TG100-115 decreases pulmonary eosinophil levels and accumulation of IL-13 and mucin in animal models of asthma and chronic obstructive pulmonary disorder (COPD), decreasing inflammation. TH100-115 also inhibits edema and inflammation induced by VEGF and platelet activating factor (PAF) in other animal models, decreasing development of infarcts and improving cardiac function. As a result of its cardioprotective activity, TG100-115 is currently in clinical trials as a potential treatment to reduce acute myocardial infarctions.

Product Info

Cas No.

677297-51-7
Purity

≥98%
Formula

C18H14N6O2
Formula Wt.

346.34
IUPAC Name

3-[2,4-diamino-7-(3-hydroxyphenyl)pteridin-6-yl]phenol
Solubility

DMSO 9 mg/mL (25.98 mM) Water Insoluble Ethanol Insoluble
Appearance

Yellow-Tan Powder

Shipping and Storage

Store Temp

-20°C
Ship Temp

Ambient

Downloads

MSDS

T2402 MSDS PDF
Info Sheet

T2402 Info Sheet PDF

References

Doukas J, Eide L, Stebbins K, et al. Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease. J Pharmacol Exp Ther. 2009 Mar;328(3):758-65. PMID: 19056934.

Doukas J, Wrasidlo W, Noronha G, et al. Isoform-selective PI3K inhibitors as novel therapeutics for the treatment of acute myocardial infarction. Biochem Soc Trans. 2007 Apr;35(Pt 2):204-6. PMID: 17371238.

Doukas J, Wrasidlo W, Noronha G, et al. Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury. Proc Natl Acad Sci U S A. 2006 Dec 26;103(52):19866-71. PMID: 17172449.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • V3327

    Virginiamycin Mixture

    Macrolide antibiotic

    ≥97%
  • D183740

    Desoxypipradrol

    NDRI inhibitor

    ≥98%
  • M568264

    Mogroside IIe

    Triterpenoid

    ≥98%
  • C2946

    Chlorambucil

    Nitrogen mustard, DNA alkylator.

    ≥99%
  • D324096

    Diclofenac Impurity B

    Impurity of diclofenac

    ≥98%
  • H6225

    HPGDS-inhibitor-1

    HPGDS inhibitor.

    ≥98%
  • C9711

    Cyclovirobuxine D

    Found in Buxus; hERG K+ channel inhibitor.

    ≥97%
  • C4556

    Clofibric Acid

    Metabolite of clofibrate; PPARα agonist.

    ≥98%
  • P1761

    Pepstatin

    Aspartyl protease inhibitor.

    ≥98%
  • L3550

    Limonin

    Furanolactone found in citrus fruits.

    ≥98%
  • P2997

    Phytic Acid, 40-50 wt% aqueous solution

    Saturated cyclic acid used to store phosphorus ...

    ≥40%
  • R2788

    RGW-611

    Morpholine derivative.

    ≥98%
  • F5869

    N-formyl-Met-Ala-Ser

    Peptide, involved in neutrophil activation; FPR...

    ≥95%
  • R162041

    Rebaudioside A

    Steviol glycoside used as sucrose substitute

    ≥98%
  • D0375

    Dasatinib Monohydrate

    Abl, PDGFR, EphR, Src, k-Kit, FYN, LCK, HCK inh...

    ≥98%
  • R5661

    Ropinirole Hydrochloride

    Indoline; D2/3 agonist.

    ≥99%
  • L5751

    Lomerizine Dihydrochloride

    L-type and T-type Ca2+ and TRP antagonist.

    ≥98%
  • E7556

    Etodolac

    NSAID; TRPA1 agonist, COX-2 inhibitor.

    ≥98%
  • C224760

    CFT-7455

    Degrader of IKZF1/3

    ≥98%
  • A6269

    Apremilast

    PDE4 inhibitor.

    ≥98%